10X GENOMICS INC-CLASS A (TXG)

TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative

/PRNewswire/ -- French TechBio startup Cure51 and 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that Cure51...

10x Genomics Reports Third Quarter 2024 Financial Results

/PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended...

10x Genomics Delivers 'Single Cell for a Single Cent' with New Chromium Launches

/PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of two new Chromium products intended...

10x Genomics Crashes After 'Disruptive' Reorg Upsets Third-Quarter Sales

The company is undergoing a reorganization that has proven more "disruptive" than previously expected.

10x Genomics Announces Preliminary Select Third Quarter 2024 Results

/PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary select results for the third quarter...

10x Genomics Announces Mega-Scale Single Cell Analysis for One Cent Per Cell at Human Cell Atlas General Meeting

/PRNewswire/ -- At the Human Cell Atlas General Meeting held September 29-30 in Milan, Italy, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and...

First Week of TXG May 2025 Options Trading

10x Genomics Unveils Chromium Xo: A Low-Cost Instrument to Expand Access to High-Performance Single Cell Research

/PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced the launch of Chromium Xo, a new addition to its...

10x Genomics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

/PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will...

TXG Stock Earnings: 10x Genomics Beats EPS, Beats Revenue for Q2 2024

TXG stock results show that 10x Genomics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

10x Genomics Reports Second Quarter 2024 Financial Results

/PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended...

10x Genomics Technology Supports TenK10K Project Led by Garvan Institute of Medical Research to Help Transform the Treatment of Complex Diseases

/PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today its involvement in TenK10K, a large-scale,...

10x Genomics to Report Second Quarter 2024 Financial Results on August 8, 2024

/PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the...